Results for "[:.]-CA:.)--AS"

Cancer antigen 15.3 (CA 15-3) should only be used to determine response to therapy in patients with metastatic breast cancer or for the early detection of recurrence in patients with previously treated stage II and stage III breast cancer. Requests should therefore only be made as advised by the specialist secondary care team.

As with most tumour markers there is a high incidence of false positive and false negative results. CA 19-9 is most appropriately used in monitoring disease progression or effectiveness of treatment once diagnosis of the tumour has been made and serum concentrations have been shown to be raised prior to treatment (Lewis negative individuals do not express CA 19-9).